genXone S.A.

GX1

PLGENXN00013

Pharmaceuticals

End-of-day quote Warsaw S.E. Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
5.92 ^PLN	-1.33%		-7.79%	+10.04%

Feb. 12	GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 12	GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2022

February 10, 2023 at 11:04 am EST

genXone S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was PLN 10.59 million compared to PLN 23.2 million a year ago. Net income was PLN 0.480285 million compared to PLN 8.77 million a year ago.

Latest news about genXone S.A.

GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 12	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 12	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-10	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-10	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-11	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
An unknown buyer acquired 14.3% stake in genXone S.A. from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	21-06-06	CI
Genxone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-12	CI
GenXone S.A. has completed an IPO in the amount of PLN 7.3544 million.	20-08-25	CI
GenXone S.A. announced that it has received PLN 4.14 million in funding from INC S.A.	20-04-15	CI
GenXone Raises USD 1 Million in Private Placement	20-04-15	CI
Medcamp S.A. agreed additional 34% stake in genXone S.A from Torox Eko FIZAN fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	20-03-12	CI
GenXone S.A. has filed an IPO in the amount of PLN 4.002 million.	19-11-21	CI
Medcamp S.A. acquired 29.84% stake in GENXONE sp. z o.o. for PLN 0.39 million.	17-09-12	CI

Chart genXone S.A.

Duration

Period

More charts

Company Profile

Genxone SA is a Poland-based company, which specializes in NGS (next generation sequencing) and medical diagnostics. The Company is involved in the development and marketing of nanoforming technology in the field of science, business and medicine and cooperates as a commercial partner with Oxford Nanopore Technologies - biotechnological innovation entity.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GENXONE S.A.	+10.04%	4.96M
KYOWA KIRIN CO. LTD.	+9.28%	8.74B
SK BIOPHARMACEUTICALS CO., LTD.	-14.24%	4.94B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.95%	4.7B
YUHAN CORPORATION	+5.96%	3.98B
BETTA PHARMACEUTICALS CO., LTD.	-23.57%	2.28B
INDIVIOR PLC	+15.27%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+17.77%	2.14B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.28%	2.12B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B